BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?Zacks Investment Research • 09/12/25
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 09/09/25
Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trialReuters • 09/08/25
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology LeadershipSeeking Alpha • 09/07/25
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend YieldsBenzinga • 09/04/25
8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August ReportSeeking Alpha • 08/31/25
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025Business Wire • 08/29/25
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 08/29/25
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025Business Wire • 08/25/25
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerPRNewsWire • 08/18/25